A randomized, double-blinded, placebo-controlled multicenter phase II trial of adjuvant immunotherapy with tecemotide (L-BLP25) after R0/R1 hepatic colorectal cancer metastasectomy (LICC): Final results.

Schimanski, CC; Kasper, S; Hegewisch-Becker, S; Schroeder, J; Overkamp, F; Kullmann, F; Bechstein, WO; Vohringer, M; Oellinger, R; Lordick, F; Heinemann, V; Geissler, M; Schulz-Abelius, A; Linz, B; Bernhard, H; Schoen, MR; Greil, R; Smith-Machnow, V; Schmidtmann, I; Moehler, MH

View this publication in the PUBMED database